Results 131 to 140 of about 67,405 (197)

A Single Dose of Yellow Fever Vaccine Provides Long-Term Immunity in Japanese Travelers. [PDF]

Vaccines (Basel)
Fukushima S, Lim CK, Hamada A.
europepmc   +1 more source

Safety and Immunogenicity of the Attenuated Yellow Fever Vaccine in Several Neotropical Primate Species. [PDF]

Vaccines (Basel)
Paula NF, Vieira AD, Santos DOD, Souza LDR, Coelho CM, Tinoco HP, Lima PCS, Motta ROC, Pereira VDS, Carvalho MPN, Fernandes CB, Azevedo AS, Arruda MS, Costa TA, Drumond BP, Leme FOP, Freire MDS, Paixão TAD, Oliveira AR, Santos RL.   +19 more
europepmc   +1 more source

Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study. [PDF]

Trials, 2022
Mackenzie GA, Osei I, Salaudeen R, Secka O, D'Alessandro U, Clarke E, Schmidt-Chanasit J, Licciardi PV, Nguyen C, Greenwood B, Mulholland K.   +10 more
europepmc   +1 more source

Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to standard dose in children 9-23 months old in Uganda, 2019-2022 - final report. [PDF]

Vaccine
Lee SE, Najjengo M, Shaum A, Sekiziyivu AB, Carlock G, Casey RM, Lubega I, Tumwine C, Twinomuhwezi-Oyet E, Nakato WN, Sciarratta CN, Hyde TB, Chu SY, Doshi RH, Kambugu A, Gidudu JF.   +15 more
europepmc   +1 more source

Safety and immunogenicity of the yellow fever vaccine for patients with end-stage renal disease. [PDF]

J Bras Nefrol
Distenhreft JIQ, Couto-Lima D, Andreazzi CS, Thomazini JFRC, Vasconcellos Filho LM, Falqueto A, Luchi WM.   +6 more
europepmc   +1 more source

Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial. [PDF]

PLoS Negl Trop Dis, 2023
Sandberg JT, Löfling M, Varnaitė R, Emgård J, Al-Tawil N, Lindquist L, Gredmark-Russ S, Klingström J, Loré K, Blom K, Ljunggren HG.   +10 more
europepmc   +1 more source

Basal T cell activation predicts yellow fever vaccine response independently of cytomegalovirus infection and sex-related immune variations. [PDF]

Cell Rep Med
Santos-Peral A, Zaucha M, Nikolova E, Yaman E, Puzek B, Winheim E, Goresch S, Scheck MK, Lehmann L, Dahlstroem F, Karimzadeh H, Thorn-Seshold J, Jia S, Luppa F, Pritsch M, Butt J, Metz-Zumaran C, Barba-Spaeth G, Endres S, Kim-Hellmuth S, Waterboer T, Krug AB, Rothenfusser S.   +22 more
europepmc   +1 more source

Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals. [PDF]

An Bras Dermatol, 2021
Almeida LR, Criado RF, Criado PR, Ensina LF, Abdalla BMZ, Quaresma JAS.   +5 more
europepmc   +1 more source

Reaching Forest Workers with Yellow Fever Vaccine Through Engagement of the Private Sector in Central African Republic. [PDF]

Vaccines (Basel)
Noufack G, Bissengue P, Zobanga JK, Malingao JSC, Keita M, Razaiarimanga MC, Raguenaud ME.   +6 more
europepmc   +1 more source

Immunogenicity of a single dose of the 17DD yellow fever vaccine in a cohort of adults and children in a non-endemic area, and its association with dengue and Zika seropositivity. [PDF]

PLoS Negl Trop Dis
Saucha CVV, Maia MLS, Sousa ESS, de Oliveira PMN, Xavier JR, de Castro TDM, Cruz RLS, Schwarcz WD, Pereira RC, Azevedo AS, de Filippis AMB, Ferroco CLV, Pizzini GLC, Brum RCS, Secundino L, Andrade MFS, de Oliveira RVC, Simões M, Cerbino-Neto J, Martins-Filho OA, Campi-Azevedo AC, de Lima SMB, Camacho LAB, Collaborative Group for Yellow Fever Vaccine Studies.   +23 more
europepmc   +1 more source